Methods for assessment and treatment of depression via utilization of single nucleotide polymorphisms analysis
OwnerJay L. Lombardinventor
Life of this patent
Estimating the term…
Abstract
Described herein are assays, kits and methods for treating depression, including the diagnosis and treatment of depression based on the determination of genetic predispositions towards inhibition or enhancement of Ca2+/calmodulin-dependent protein kinase II (CaMKII). For example, described herein are methods and kits (including assays) for determining if one or more gene in an excitatory or inhibitory pathway for modulating CaMKII activity or expression is likely to be inhibited or enhanced by an SNP. Also described are methods and kits (including assays) for prescribing treatment based on the identification of SNPs that may modulate CaMKII.
Claims47
A panel assay to determine the presence of SNPs that up-regulate or inhibit CaMKII activity, the panel assay comprising:
- a plurality of SNP indicators that collectively indicate the presence or absence of one or more SNP that alters the function or expression of a gene from each of the serotonin metabolism pathway, the dopamine metabolism pathway, the glutamate metabolism pathway, and the hypothalamic pituitary adrenal axis.
A panel assay to determine the presence of SNPs that up-regulate or inhibit CaMKII activity, the panel assay comprising:
- a plurality of SNP indicators that collectively indicate the presence or absence of one or more SNP that alters the function or expression of a gene from each of the serotonin metabolism pathway, the dopamine metabolism pathway, the glutamate metabolism pathway, and the hypothalamic pituitary adrenal axis;
- and
- an interpretive comment indicating the effect of any identified SNPs on the regulation of CaMKII activity.
A panel assay to determine the presence of SNPs that up-regulate or inhibit CaMKII activity, the panel assay comprising:
- a plurality of SNP indicators that collectively indicate the presence or absence of one or more SNP that alters the function or expression of a gene from each of the serotonin metabolism pathway, the dopamine metabolism pathway, the glutamate metabolism pathway, and the hypothalamic pituitary adrenal axis;
- and
- an interpretive comment suggesting a treatment based on the identified SNPs.
A kit to determine the presence of SNPs that up-regulate or inhibit CaMKII activity, the kit comprising:
- an SNP assay indicating the presence or absence of an SNP that alters the function or expression of a gene in the serotonin metabolism pathway;
- an SNP assay indicating the presence or absence of an SNP that alters the function or expression of a gene in the dopamine metabolism pathway;
- an SNP assay indicating the presence or absence of an SNP that alters the function or expression of a gene in the glutamate metabolism pathway;
- and
- an SNP assay indicating the presence or absence of an SNP that alters the function or expression of a gene in and the hypothalamic pituitary adrenal axis.
A method of determining the presence of SNPs that up-regulate or inhibit CaMKII activity in a subject, the method comprising:
- assaying a sample of a subject's tissue for the presence of at least one SNP that alters the function or expression of a gene from each of the serotonin metabolism pathway, the dopamine metabolism pathway, the glutamate metabolism pathway, and the hypothalamic pituitary adrenal axis.
A method of determining a treatment for depression in a subject by determining the presence of SNPs that up-regulate or inhibit CaMKII activity in the subject, the method comprising:
- assaying a sample of a subject's tissue for the presence of at least one SNP that alters the function or expression of a gene from each of the serotonin metabolism pathway, the dopamine metabolism pathway, the glutamate metabolism pathway, and the hypothalamic pituitary adrenal axis;
- proposing a treatment for depression based on the presence the SNP detected by assaying the sample.
A method of determining a treatment for depression in a subject by determining the presence of SNPs that up-regulate or inhibit CaMKII activity in the subject, the method comprising:
- assaying a sample of a subject's tissue for the presence of at least one SNP that alters the function or expression of a gene from each of the serotonin metabolism pathway, the dopamine metabolism pathway, the glutamate metabolism pathway, and the hypothalamic pituitary adrenal axis;
- determining the net effect of any SNPs detected by assaying the sample on CaMKII activity;
- and
- proposing a treatment for depression that inhibits CaMKII activity if the net effect is to up-regulate CaMKII activity, or that preferentially activates CaMKII activity if the net effect down-regulates CaMKII activity.
Dependencies are inferred from the claim text.